Drug resistance in breast cancer has been increasingly associated with alterations to the plasma membrane lipidome. The abstract highlights two recurrent lipidomic signatures in resistant cells: loss of lipid asymmetry and increased levels of cholesterol (CHL) and sphingomyelin (SM). These changes are hypothesized to modify membrane physical properties in ways that could alter drug permeability. The study applied computational approaches to elucidate how such lipidomic remodeling affects the ability of tamoxifen (TAM) to cross the bilayer.
The authors constructed eight distinct lipid bilayer models spanning normal asymmetric membranes (labeled N1 and N2) through several cancer-mimetic symmetric states (labeled C1–C5). Simulations were carried out at both all-atom and coarse-grained resolutions to capture complementary length- and time-scale information. To probe TAM permeation energetics, they used unbiased molecular dynamics alongside umbrella sampling to calculate potential of mean force (PMF) profiles across the different membrane models.
Comparative analysis of the simulated bilayers showed that membrane symmetrization combined with enrichment in cholesterol and sphingomyelin produced a condensed lipid state. This condensation manifested as increased bilayer thickness (D_HH), a decreased area per lipid (APL), and reduced lateral fluidity. These physical parameter changes are consistent with a transition toward a more ordered, less permeable membrane domain when CHL/SM levels are elevated and lipid asymmetry is lost.
PMF profiles derived from umbrella sampling revealed model-specific differences in TAM permeation. In some cancer-mimetic membranes (for example, the base cancer model C2), TAM permeated relatively freely across the bilayer. By contrast, membranes that were particularly enriched in CHL and SM (notably the models labeled C3 and C4) acted as strong energetic barriers to TAM penetration. The abstract specifies that these CHL/SM-rich membranes impose severe energetic impediments to the drug’s passage into the bilayer core.
In rigid, CHL/SM-enriched bilayers TAM was not only hindered from penetrating but was also observed to become strongly trapped within specific hydrophobic regions of the membrane. The simulations identified energy minima for these trapped states of approximately −38 kJ mol−1. Such deep minima indicate favorable microenvironments where TAM can become sequestered, limiting its progression further into the membrane core and thereby reducing transmembrane permeation.
The simulated results link lipidomic alterations directly to reduced tamoxifen permeability at the molecular level. Based on these findings, the authors suggest two potential therapeutic strategies: targeting membrane lipid metabolism to reverse or prevent the CHL/SM enrichment and lipid symmetrization that produce condensed membranes, or designing adjuvant agents that modulate membrane lipids to restore drug permeability. These strategies are framed as promising approaches to overcome drug resistance driven by membrane remodeling.
The abstract focuses on computational molecular dynamics results and does not report experimental or in vivo validation within the text provided. Specifics such as quantitative composition of each membrane model beyond their labels (N1, N2, C1–C5), simulation lengths, system setup details, or any experimental correlation were not reported in the abstract. Likewise, no direct data on how proposed lipid-targeting interventions perform in cellular or animal models were provided in the source material.
Multi-scale MD simulations of eight lipid bilayer models demonstrate that membrane symmetrization and CHL/SM enrichment drive lipid condensation (increased D_HH, reduced APL, lowered lateral fluidity) that alters transmembrane drug transport. PMF analysis indicates that while some cancer-like membranes permit tamoxifen permeation (e.g., C2), CHL/SM-rich resistant membranes (C3, C4) form severe energetic barriers and trap the drug in hydrophobic sites (energy minima ~−38 kJ mol−1). The work provides a mechanistic, molecular-level explanation for how lipidomic remodeling can underlie tamoxifen resistance and proposes targeting membrane lipid metabolism or using lipid-modulating adjuvants as potential strategies. Details beyond the simulation results—such as experimental confirmation, full model compositions, and simulation parameters—were not reported in the abstract.